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Bifidobacterium animalis subsp. lactis IPLA 20020 and Lactobacillus gasseri IPLA 20212, two strains isolated from human samples,
were evaluated for safety and influence over the intestinal microbiota and cytokine production by the intestinal tissue of adult
BALB/c mice. Mice were divided into four groups receiving during 8 days PBS or a suspension of each strain, prepared fresh or
lyophilized (bifidobacteria), at an amount of 4x108 viable cells/day. This dose could be comparable to the probiotic intake of a
human adult who consumed about 100-200 mL of functional fermented milk per day, considering the usual level of probiotics
in commercial products. No microbial translocation to liver or alterations in food intake, weight, and behavior were observed
in treated mice. Intestinal content of secretory immunoglobulin A (s-IgA) was not affected, discarding any adverse effect on the
mucosa-associated immunity.The profile of intestinal proinflammatory/regulatory cytokines after intervention evidenced that the
microbial strain administered and its cellular state (fresh or lyophilized) as well as the host tissue analyzed (small or large intestine)
influenced the immune response and suggests a moderate shift towards a T helper 1 profile (Th1) in the large intestine after the
administration of both strains. Changes on relative levels of some intestinal microbial groups were evidenced after intervention.
It is noteworthy that butyrate was positively associated with a balanced pro-Th1 immune response. Therefore, B. animalis subsp.
lactis IPLA20020 and L. gasseri IPLA 20212 could be considered potential probiotic candidates to be included in functional foods
for balancing the intestinal immune response.
1. Introduction
Probiotics are defined as live microorganisms that when
administered in adequate amounts confer a health benefit
to the host [1]. Although they are usually administered
included in food, some lyophilized preparations are also
available in the market as supplements [2]. The benefi-
cial effects attributed to probiotics are strain specific and
require demonstration in expensive and time-consuming
human intervention studies, which frequently fail to confirm
previous in vitro observations [3]. The use of animal models
is an affordable intermediate step, recommended for the
selection of suitable probiotics [1].
Microorganisms from Lactobacillus and Bifidobacterium
genera constitute themost frequently used human probiotics,
being relatively easy to produce them in large scale as frozen
or freeze-dried cultures [4]. Due to their long history of safe
use, some of their species have the “Qualified Presumption
of Safety” (QPS) status recognized by the European Food
Safety Authority (EFSA) [5]. Breast milk and fecal samples
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of newborns represent a good source of potential probiotics
from the genera Bifidobacterium and Lactobacillus [6, 7].
The gastrointestinal tract (GIT) is the first line of action
of probiotics, where they can interact directly with cells
from GIT epithelium and cells from the immune system and
they can modulate the intestinal microbiota composition and
their subsequent interaction with the host [8]. Therefore, the
knowledge of the immune modulation profile of potential
probiotics at the intestinal level could facilitate the selection
of strains tailored for their specific immune properties and
safety for human consumption in foods [9].
FAO/WHO [10] recommends intervention studies in
animals, mainly rodents, as a previous step to the human
intervention studies definitely proving functionality of probi-
otics. BALB/c is the most frequently usedmice strain to study
functionality and mechanisms of action of probiotics and has
been recommended for the assessment of the immunomod-
ulatory capacity of lactic acid bacteria [11]. Bifidobacterium
animalis subsp. lactis IPLA 20020 and Lactobacillus gasseri
IPLA 20212 are two strains previously isolated by us from
infant feces and breast milk, respectively [7]. The aim of
the present study was to perform a preliminary evalua-
tion of these strains as potential probiotics by determining
their safety and influence on the pattern of gut cytokines
and on the intestinal microbiota profile of adult BALB/c
mice.
2. Materials and Methods
2.1. Microorganisms and Growth Conditions. Microbial
strains were reactivated from frozen stocks by overnight
incubation at 37∘C in MRS broth (Biokar Diagnostics,
Beauvais, France), being added with 0.1% (v/v) L-cysteine
(Sigma Chemical Co., St Louis, MO, USA) for the cultivation
of Bifidobacterium. In the case of the bifidobacteria,
incubation was carried out in anaerobic conditions, as
previously specified [7]. For the preparation of strains to
be administered to experimental animals, MRS broth was
inoculated (1% w/v) with the corresponding overnight
microbial cultures and then pellets were washed with
sterile PBS and resuspended in the same buffer. In order to
determine whether the format of administration of strains
could influence the results obtained, part of the B. animalis
subsp. lactis suspension was also freeze-dried; with this
aim, pelleted overnight cultures were resuspended in 10%
(w/v) sucrose, kept at -80∘C in sterilized glass tubes for 24
h and then lyophilized in a Freezemobile 12EL equipment
(VirTis, Gardiner NY, USA) for 24 h. Fresh inocula of
Bifidobacterium and Lactobacillus strains as well as the
lyophilized bifidobacteria were prepared at a concentration
of 2x109 cfu/mL in PBS and were administered to mice.
2.2. Animals and Experimental Design. The experiments
with animals were approved by the Ethical Committee for
Animal Experimentation of the Facultad de Ciencias Veteri-
narias, Universidad Nacional del Litoral (Esperanza, Santa
Fe, Argentina). Subsequent handling strictly followed the
European Communities Council Directive of November 24,
1986 (86/609/EEC). Twenty-one six-week-old male BALB/c
mice (22 ± 1 g body weight) were obtained from the Ran-
dom Bred Colony at the Centro de Medicina Comparada,
Instituto de Ciencias Veterinarias del Litoral (CMC-ICiVet-
Litoral, CONICET–UNL), Facultad de Ciencias Veterinar-
ias, Universidad Nacional del Litoral (Esperanza, Santa Fe,
Argentina) and were maintained at the INLAIN animal
facility for 7 days before the trial began. Animals were kept
in a controlled environment at a temperature of 21 ± 2∘Cwith
humidity at 55 ± 2% and 12 h light-dark cycle during all the
intervention. All animals received ad libitum sterile tap water
and a sterile high-protein and normal carbohydrate balanced
diet (Cooperación, Buenos Aires, Argentina) containing per
kg 320 g carbohydrates, 230 g proteins, 75 g total fat, 60
g raw fiber, 100 g total minerals, 13 g Ca, 8 g P, 120 g
water, and vitamins. This dietary profile is routinely used
in our laboratory for optimal metabolic performance of
mice, following the US Department of Agriculture (USDA)
recommendations [12].
Mice were simultaneously divided into four experimental
groups of 5-6 animals each and housed in plastic cages.
Animals received daily by oral gavage during 8 days 0.2
mL of PBS solution with different bacterial preparations,
as follows: group (1) fresh B. animalis subsp. lactis IPLA
20020, group (2) lyophilized B. animalis subsp. lactis, group
(3) fresh L. gasseri IPLA 20212, and group (4) control: no
microorganism administered. Feces frommicewere collected
from cages at day 0 and day 8 of intervention, immediately
frozen at -80∘C, and freeze-dried. Weight of animals, food
consumption, and mortality were monitored daily; animals
were also observed daily for possible abnormal behavior. At
the end of the intervention period, animals were anesthetized
individually by an intraperitoneal injection of a ketamine-
xylazine-acepromazine cocktail. Animals were sacrificed by
cervical dislocation. The liver and small and large intestines
were aseptically excised from dead animals. Intestinal fluid
was obtained by flushing the small intestine with 5mL of PBS
[13] added with a protease inhibitor cocktail (Sigma P8340)
(1% v/v). Intestinal fluid and small and large intestine tissue
samples were kept at -70∘C until processing whereas liver
samples were processed immediately.
2.3. Liver Cultivation. Liver samples were suspended imme-
diately after collection in 1/10 sterile PBS solution and
homogenized (Ultra Turrax T8, Ika Labortechnik, Staufen,
Germany) for 30 seconds; serial dilutions in PBS buffer were
deep-plated into VRBL agar (Biokar, Beauvais, France) and
incubated 24 h at 37∘C for enterobacteria counting to assess
intestinal bacterial translocation.
2.4. Determination of Intestinal Immune Parameters. Intesti-
nal fluid and small and large intestine tissue samples were
kept at -70∘C until processing for secretory IgA (s-IgA)
and cytokine determination. Cytokines (TNF𝛼, IFN𝛾, IL-
10, IL-6, IL-12, and IL-2) were determined by ELISA in
intestinal tissue homogenates, using commercial kits (BD
Biosciences Pharmingen, San Diego, CA, USA). For prepar-
ing homogenates, intestinal tissue samples were suspended
in PBS containing 1% (v/v) antiprotease cocktail (Sigma), 10
mM EDTA (Sigma), and 0.05% (v/v) Tween 20 (Sigma) in a
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proportion of 1 mL PBS per 100 mg tissue and were homog-
enized for 30 seconds (Ultra Turrax T8) and centrifuged
(9500xg, 10 min, 4∘C) and the supernatants were collected
and kept frozen until use. S-IgA was quantified by ELISA in
intestinal fluids collected as indicated before [14].
2.5. Analysis of Microbial Communities in Fecal Samples.
Assessment of fecal microbial groups was made by qPCR.
The DNA was obtained from lyophilized fecal samples
diluted 1/10 in PBS by using the QIAamp DNA stool mini
kit (Qiagen, Hilden, Germany). PCR amplification of the
16S rRNA gene for the quantification of different bacterial
groups (Bacteroides–Prevotella–Porphyromonas group, Bifi-
dobacterium, Akkermansia, Clostridium cluster XVIa, Lac-
tobacillus group, and Faecalibacterium) and levels of total
intestinal bacteria was performed in a 7500 Fast Real-Time
PCR System (Applied Biosystems, Foster City, CA, USA)
using the SYBRGreen PCRMasterMix (Applied Biosystems)
as described previously [15]. Samples were analyzed in dupli-
cate in two independent PCR runs. Data of lyophilized fecal
samples were normalized for comparison. In this way, the
relative abundances of the different microbial groups were
calculated as a percentage of the total microbial levels in each
sample; percentage of variations of the relative abundance for
each microbial group after 8 days of intervention were then
referred to as the relative abundance of this group at time 0
considering this as 100%.
Analysis of the major short chain fatty acids (SCFA:
acetic, propionic, and butyric acids) was performed in a
1/10 PBS dilution of the lyophilized fecal sample. A gas
chromatograph 6890N (Agilent Technologies Inc, Palo Alto,
CA, USA) connected to a mass spectrometry (MS) 5973N
detector (Agilent Technologies) and to a flame ionization
detector (FID) was used as described previously [16]. Samples
were analyzed in triplicate and the molar proportion of each
SCFA was calculated as the concentration (mM) percentage
of such compound referred to as the total SCFA (sum of
concentrations of the three major SCFA: acetic, propionic,
and butyric acids). Increments in the molar proportion of
each of the major SCFA at the end of the intervention (day 8)
were calculated with respect to the initial molar proportion
for each compound at time 0.
2.6. Statistical Analyses. Statistical analysis of results was
performed using the software SPSS v.24 (SPSS Inc., Chicago,
USA). Data were compared among the different groups
of mice administered probiotics and the control group
at the end of the intervention. For variables showing a
normal distribution (Shapiro-Wilk and Levene tests), one-
way ANOVA followed by post hoc DMS comparison was
conducted (increments of acetic, propionic, and butyric acids,
acetic to propionic and acetic to butyric acids ratios in
feces; s-IgA in intestinal fluid; IL-10, Il-6, and IFN𝛾 in the
small intestine tissue; TNF𝛼, and IL-6 in the large intestine
tissue). In the remaining cases (variables showing nonnormal
distribution) a Kruskal-Wallis test and a Dunn’s test of
pairwise comparisons were applied. To get deep into the
associations between the microbiota and the cytokines in the
large intestine tissue, a Spearman correlation analysis was
conducted considering together all the animals of our study.
A heatmap was generated under R Studio version 1.1.456
package heatmaply. A significant p value of 0.05 was used for
the interpretation of results.
3. Results and Discussion
The amount of bacteria administered to mice in our study
is comparable to the dose of probiotic received per unit of
body weight by a human adult consuming 100-200 mL of
fermented milks containing about 109 viable probiotics per
mL. Safety is one of the most important criteria for the selec-
tion of probiotics. No death or unexpected changes in food
intake or behavior were observed for any of the animal groups
receiving Bifidobacterium and Lactobacillus strains and no
statistically significant differences in the animal weight were
noticed among the four groups of mice during the treatment
(data not shown). This indicates that general parameters
of well-being were not affected by the administration of L.
gasseri IPLA 20212 and B. animalis subsp. lactis IPLA 20020
strains to BALB/c mice. In addition, no microbial counts
were obtained after the intervention from the cultivation
of liver tissue, one of the first reliable signals of microbial
translocation, evidencing that the oral administration of the
microorganisms did not promote bacterial translocation.
Therefore, no adverse systemic effects were noticed by the
administration of the two microbial strains to mice at levels
comparable with those of human consumers of fermented
milks containing probiotics.
S-IgA is the most abundant antibody in the mucosal
secretions and plays a key role in the defense against
pathogens. S-IgA levels determined in the intestinal fluid did
not show any significant variation between the groups of
mice after the period of administration of the Bifidobacterium
and Lactobacillus strains (mean ± standard deviation: 11.23
± 2.39 𝜇g/mL in the control group, 8.96± 1.53 𝜇g/mL in
mice fed fresh Bifidobacterium, 11.57 ± 2.85 𝜇g/mL in mice
fed lyophilized Bifidobacterium, and 10.57 ± 4.40 in mice
fed Lactobacillus). These results indicate that s-IgA is being
produced similarly by all groups of animals, allowing us to
rule out possible adverse effects on the mucosa-associated
immunity by the microorganisms administered.
We determined the levels of different cytokines in tissue
homogenates of small and large intestine from the four
groups of mice after the treatments (Figures 1(a)–1(f)). The
effects promoted by the administration of B. animalis subsp.
lactis IPLA 20020 or L. gasseri IPLA 20212 were moderate,
differed between the small and large intestine tissues, and
varied depending on themicrobial strain administered and its
cellular state. In this respect, it has been previously reported
that different strains may promote different responses, induc-
ing even opposite immune effects [17, 18]. Specifically, in
the present work we found differences among mice groups
for TNF𝛼, IFN𝛾, and IL-12 in the small intestine tissue
whereas in the large intestine differences for IL-10 and IL-6
were found. Regarding the small intestine, the administration
of a fresh culture of B. animalis subsp. lactis IPLA 20020
promoted lower levels of TNF𝛼 whereas the lyophilized
preparation of the same microorganism increased IL-12 with
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Figure 1: Cytokines ((a) to (f)) (pg/mL) in tissue of small intestine (left part of graphs) and large intestine (right part of graphs) and cytokine
ratios in the large intestine ((g) to (i)) of BALB/c mice after a daily administration during 8 days of the vehicle (PBS) (white boxes), fresh
B. animalis subsp. lactis IPLA 20020 (grey boxes), lyophilized B. animalis subsp. lactis IPLA 20020 (dotted grey boxes), and fresh L. gasseri
IPLA 20212 (striped white boxes). For each cytokine and cytokines ratio, the box and whiskers plot represents median, interquartile range,
and minimum and maximum values obtained from each group of animals. A one-way ANOVA test and a DMS post hoc test were used to
compare IL-10, IL-6, and IFN𝛾 in the small intestine and TNF𝛼 and IL-6 in the large intestine tissues among the four groups of mice whereas
the nonparametric Kruskal-Wallis and pairwise comparison with Dunn’s tests was applied to the comparison of TNF𝛼 in the small intestine
tissue, INFΥ and IL-10 in the large intestine tissue, and IL-2, IL-12 and TNF𝛼/IL-10, IFN𝛾/IL-10, and IL10/IL-12 ratios in the small and large
intestine tissues among the four groups of animals. Different letters above the boxes indicate significant differences in small intestine, large
intestine, and cytokine ratios in the large intestine, among the four groups of animals receiving different probiotics or vehicle (p < 0.05).
respect to the control group; regarding the IFN-𝛾, only the
lyophilized preparation of the bifidobacteria was able to
promote a decrease in the levels of this cytokine. In the
large intestine tissue of mice fed either B. animalis subsp.
lactis IPLA 20020 or L. gasseri IPLA 20212, the levels of
IL-10 decreased significantly regarding the control group,
which was accompanied by a concomitant increase of IL-
6 in animals receiving the Bifidobacterium strain (either
administered fresh or lyophilized).
Since cytokines do not act in an isolated way, the
predominant type of immune response depends on the
balance between different cytokines. High levels of IL-10
with respect to IL-12 may redirect the immune response
towards a type Th2 or a T regulatory response. Moreover,
IL-10 and TNF𝛼 are cytokines mutually regulated and with
opposite roles in inflammation, so that their relative balance
is important for controlling deviations on the immune
responses. Therefore, several ratios between cytokines that
are relevant for dendritic cell induced T lymphocyte differen-
tiation responses were calculated to predict the Th-cell type
of predominant response induced in the intestinal tissue of
mice by the administration of ourmicrobial strains (IL-10/IL-
12, TNF𝛼/IL-10, and IFN𝛾/IL-10) (Figures 1(g)–1(i)). In this
respect, it is also interesting to consider that BALB/cmice nat-
urally display a Th1/Th2 balance towards Th2 response [19],
whichmakes these animals useful for assessing shifts towards
Th1 responses promoted by different agents. Regarding our
results, in the large intestine, a moderate but statistically
significant increase of the TNF𝛼/IL-10 and IFN𝛾/IL-10 ratios
occurred following the administration of fresh cultures of
either the two strains whereas the bifidobacteria (either
fresh or lyophilized) promoted a decrease of the IL-10/IL-12
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Table 1: Percentage of variation (Δ) with respect to time 0 (considered as 100%) of the relative abundance of different intestinal microbial
groups (Table S1) after eight days of daily administration to adult BALB/c mice of vehicle (PBS), B. animalis subsp. lactis IPLA 20020 (fresh
or lyophilized), and fresh L. gasseri IPLA 20212. “Others” refers to the rest of microbial groups not determined in the present work. The
nonparametric Kruskal-Wallis and pairwise comparison with Dunn’s test were used to compare the four groups of mice. Different letters in














-0.59 ± 18.00 -13.51 ± 17.19 -14.47 ± 25.41 -13.20 ± 12.80
Δ Bifidobacterium 33.84 ± 58.36 11.16 ± 38.27 49.26 ± 96.98 39.11 ± 63.89
Δ Lactobacillus-
Weissella -57.31 ± 32.60
a 183.35 ± 355.62ab 271.12 ± 309.88b 353.10 ± 483.71b
Δ Enterobacteriaceae 262.40 ± 232.18b 169.54 ± 262.98b 63.63 ± 101.26ab -40.26 ± 31.67a
Δ Clostridium cluster
XIVa 219.30 ± 320.62 -18.02 ± 72.05 33.07 ± 172.02 -18.11 ± 23.91
Δ Others -10.54 ± 144.45 24.83 ± 29.66 171.26 ± 341.33 30.65 ± 34.65
ratio. Therefore it is reasonable to expect that both strains
promote a moderate shift towards a Th1 response, which in
the case of the Bifidobacterium strain could be regulated by
the concomitant increase in IL-6 levels. The effect promoted
in the small intestine by the administration of B. animalis
subsp. lactis IPLA 20020 and L. gasseri IPLA 20212 is less
conclusive, as the variations on cytokines did not result in
any significant change in cytokine ratios that could suggest
a modulation of the immune response (data not shown).
A similar pattern of immune modulatory profile, with a
moderate enhancement of the production of proinflamma-
tory cytokines and a cytokine balance favoring Th1 cellular
immunity, has been previously reported for some Lactobacil-
lus and Bifidobacterium strains in rodent models [20–22].
Early infancy is characterized by an immature andTh2-biased
immune system; the postnatal T helper cell maturation and
functionality are mainly driven by the interaction between
the gut associated lymphoid tissue and microbiota, tending
to favor a Th1 polarization and the subsequent Th1-Th2
homeostasis [23, 24]. Considering that the two strains tested
in our study were isolated in the neonatal period (from feces
of a 2-day-old full-term vaginally delivered breast-fed infant
and from breast milk, for B. animalis subsp. lactis and L.
gasseri strains, respectively), this could be related with the
Th1-biased immunity promoted by these microorganisms on
the intestinal tissue of mice [23].
Interestingly, our results indicate that the form of admin-
istration of microorganisms may influence the final results
obtained. In this regard, some authors have previously indi-
cated that technological processes and cellular state canmod-
ify the immunomodulating capability of probiotic bacteria
[25–27].
In a next step we wanted to know whether the admin-
istration of the strains affected the intestinal microbiota.
Thus, the relative levels with respect to the total microbial
counts of some relevant intestinal microbial groups were
determined before and after the administration of B. animalis
subsp. lactis IPLA 20020 or L. gasseri IPLA 20212 (Table
S1). Counts of Akkermansia, below the detection limit of the
technique (< 3 log n∘ cells/gram), and the low levels obtained
for Faecalibacterium as compared to total bacteria prevented
extracting any conclusion for these two microbial groups
(data not shown). We further determined the percentage
of variation within each group of mice of the intestinal
microbial groups at the end of treatment (with respect to time
0) and then compared these values among mice receiving
different treatments (Table 1).The fecal levels of Lactobacillus-
Weissella decreased in control mice along the intervention
but increased in animals treated with B. animalis subsp.
lactis (administered either fresh or lyophilized) and L. gasseri;
this resulted in significantly higher levels of Lactobacillus-
Weissella at the end of the intervention for those mice
receiving B. animalis or L. gasseri. On the other hand, Enter-
obacteriaceae increased along intervention both in control
mice and in those administered Bifidobacterium whereas
animals receiving L. gasseri experienced a decrease of this
intestinal microbial group, which gave rise to significantly
lower levels of enterobacteria at the end of the intervention
in mice receiving L. gasseri with respect to the other groups
of mice. Lactobacillus is among the most abundant intestinal
microorganisms in mice [28] and its increase together with
decreases in Enterobacteriaceae has been related with benefi-
cial health parameters in murine models displaying dysbiosis
associated to diseases [29–31]. No differences or clear trends
were observed for the other fecal microbial groups analyzed.
Moreover, molar proportions of fecal SCFA were calculated
at time 0 and after 8 days of treatment (Table S2). No
significant differences in the variations of molar proportions
of acetic, propionic, and butyric acids as well as in the acetic
to propionic and acetic to butyric acid ratios were found at the
end of the treatment with respect to time 0, when comparing
the different groups of mice (data not shown).
We further looked for possible associations between
immune parameters and the microbiota at the end of the















































Figure 2: Spearman correlation between cytokines in the large intestine tissue and fecal microbiota of the whole mice population used in
this work after 8 days of administration of vehicle (PBS), B. animalis subsp. lactis IPLA 20020 (fresh or lyophilized) and fresh L. gasseri IPLA
20212. Columns correspond to fecal SCFA (molar proportions), fecal SCFA ratios, and relative abundance of intestinal microbial groups
(Table S1); rows correspond to cytokines and some relevant ratios among them. Blue and red colors denote negative and positive associations,
respectively. The intensity of the colors represents the degree of association between cytokines determined in the large intestine and the
intestinal microbiota and SCFA. Asterisks indicate significant associations: ∗p < 0.05; ∗∗ p < 0.01.
intervention period in the whole set of animals used in
this work. The IL-10/IL-12 ratio associated inversely with the
intestinal molar proportions of butyric acid and directly with
the acetic to butyric acids ratio (Figure 2). Butyric acid is
an essential metabolite in the colon, being the main energy
source for colonocytes, contributing to the maintenance of
the gut barrier and acting, as well as other SCFA, on the
innate and adaptive immune responses [32]. A moderate
increase of butyric acid concentrations and a decrease of the
acetic to butyric acids ratio have been generally considered
beneficial for adult’s health [33] whereas in infants a delayed
shift in the production of butyric acid could reflect an altered
intestinal colonization [6]. We also found an inverse asso-
ciation between the proinflammatory cytokines TNF𝛼 and
IFN𝛾 with some of the fecal microbial groups (mainly Lac-
tobacillus and Bacteroides-Prevotella-Porphyromonas); inter-
estingly, the IL-10/IL-12 ratio appears to be associated with
Clostridium cluster XIVa, a group known as butyric acid
producer, whereas the ratio TNF𝛼/IL-10 directly correlated
with other unknown members of the intestinal microbiota.
These associations suggest the involvement of other intestinal
microorganisms not analyzed in the present work, directly
or through interactions with other members of the intestinal
microbiota, in the production of butyric acid.
The potential probiotic strains used in the present study
could be applied in infants presenting a delayedTh1 polariza-
tion of the immune response or in adults having weakened
Th1 response. Yet, both species studied are considered to
possess core benefits, according to the approach presented
by Hill et al. [1]. Health Canada, for instance, incorporated
this approach to their legal frame and acknowledges pro-
biotic properties to any strain belonging to the species of
microorganismsused in this studywhen delivered in food at a
level of 1x109 cfu per serving. Acceptable claims on Canadian
foods for these probiotics are based on their contribution to
a healthy gut microbiota. Further studies aimed at analyzing
more in depth the effects of B. animalis subsp. lactis IPLA
20020 and L. gasseri IPLA 20212 on the immune system and
on the intestinal microbiota need to be addressed in order to
know the potential applicability of these strains to be included
in fermented milks or other functional food products as well
as the human groups to which they could be applied.
4. Conclusion
Bifidobacterium animalis subsp. lactis IPLA 20020 and Lac-
tobacillus gasseri IPLA 20212, when administered to adult
male BALB/c mice, promoted a moderate shift towards aTh1
immune response profile in the large intestine tissue, which
positively associated with fecal levels of butyrate and with
changes in the relative levels of some relevant fecal microbial
groups.These effects were dependent on the strain and, in the
case of the bifidobacteria, on the format of administration of
the microorganism to animals (solutions prepared from fresh
or lyophilized cultures). Our results indicate the potentiality
as probiotics of the two strains tested and highlight the impact
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of the format of probiotic administration on the in vivo
functionality.
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[7] G. Soĺıs, C. G. de los Reyes-Gavilan,N. Fernández, A.Margolles,
and M. Gueimonde, “Establishment and development of lactic
acid bacteria and bifidobacteria microbiota in breast-milk and
the infant gut,” Anaerobe, vol. 16, no. 3, pp. 307–310, 2010.
[8] N. Yahfoufi, J. F. Mallet, E. Graham, and C. Matar, “Role
of probiotics and prebiotics in immunomodulation,” Current
Opinion in Food Science, vol. 20, pp. 82–91, 2018.
[9] T. R. Klaenhammer, M. Kleerebezem, M. V. Kopp, and M.
Rescigno, “The impact of probiotics and prebiotics on the im-
mune system,” Nature Reviews Immunology, vol. 12, no. 10, pp.
728–734, 2012.
[10] FAO/WHO., “Probiotics in food: health and nutritional prop-
erties and guidelines for evaluation,” FAO Food and Nutrition
Paper 85, Food and Agriculture Organization of the United
Nations andWorld Health Organization, Rome, Italy, 2006.
[11] S. Pavan, P. Desreumaux, and A. Mercenier, “Use of mouse
models to evaluate the persistence, safety, and immune mod-
ulation capacities of lactic acid bacteria,” Clinical and Vaccine
Immunology, vol. 10, no. 4, pp. 696–701, 2003.
[12] D. H. Pesta and V. T. Samuel, “A high-protein diet for reducing
body fat:Mechanisms and possible caveats,” Journal of Nutrition
and Metabolism, vol. 11, article 53, 2014.
[13] P. Burns, S. Oddi, L. Forzani, E. Tabacman, J. Reinheimer, and
G. Vinderola, “Variability in gut mucosal secretory IgA in mice
along a working day,” BMC Research Notes, vol. 11, article 98,
2018.
[14] A. C. P. Rodrigues, D. C. Cara, S. H. G. G. Fretez et al., “Sac-
charomyces boulardii stimulates sIgA production and the
phagocytic system of gnotobiotic mice,” Journal of Applied
Microbiology, vol. 89, no. 3, pp. 404–414, 2000.
[15] A. M. Nogacka, P. Ruas-Madiedo, E. Gómez et al., “Real-time
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